194, Text: 3,968, Figures: 7, References: 38 27 Scientific category: Immunobiology and Lymphoid Neoplasms 28 29 KEY POINTS 30 • Utilizing a novel mouse model mimicking MCL patient mutations, the loss of UBR5's HECT 31 domain causes alterations in B cell development. 32 33 • UBR5 mutations lead to stabilization of UBR5 and aberrant splicing. 34 35 2 ABSTRACT 36 Coordination of a number of molecular mechanisms including transcription, alternative splicing, 37 and class switch recombination are required to facilitate development, activation, and survival of B 38 cells. Disruption of these pathways can result in malignant transformation. Recently, next generation 39 sequencing has identified a number of novel mutations in mantle cell lymphoma (MCL) patients 40 including the ubiquitin E3 ligase UBR5. Approximately 18% of MCL patients were found to have 41 mutations in UBR5 with the majority of mutations within the HECT domain of the protein which can 42 accept and transfer ubiquitin molecules to the substrate. Determining if UBR5 controls the maturation 43 of B cells is important to fully understand malignant transformation to MCL. To elucidate the role of 44
Ubr5 HECT mutant mice were developed using Easi-CRISPR as previously published 15 93 and crossed with Mb1 CRE mice (kind gift of Michael Reth). Floxed Ubr5 alleles were validated 94 by PCR using primers designed to amplify targeted alleles (supplemental materials and 95 methods). For immune stimulation, mice were immunized by intraperitoneal injection with 96 Total bone marrow (BM) and splenocytes were isolated from 6-week-old mice. B220 + cells 103 were isolated using MojoSort Streptavidin Nanobeads (Biolegend, San Diego, CA) following 104 manufacturer's protocol. B cells were cultured in RPMI 1640 Base Media (Hyclone), 10% fetal 105 bovine serum (Atlanta Biologicals), 2mM L-glutamine (Corning), 50µM 2-mercaptoethanol 106 (Corning), 20mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (Hyclone), and 1X 107 penicillin/streptomycin. Cycloheximide (Millipore) was used at a final concentration of 10µg/mL. 108 109
FlowCytometry analysis 110
For flowcytometry analysis cells were stained for 1 hour in 3% FBS in PBS. Antibodies found 111 in supplemental materials and methods. For cell cycle analysis, cells were fixed and permeabilized 112
following Biolegend intracellular staining protocol and stained with Ki67 and DAPI (4', . 114 115 ELISA 116
Mice were bled on Day 0 and Day 8 following immune stimulation. Serum was collected 117
following Abcam ELISA sample preparation guide, diluted 1:10 with PBS. SRBC, diluted 1:10 in 118 PBS, was used as a control for cross reactivity of antibodies due to presence of SRBC. ELISA was 119 performed with positive reference antigen mixture, and PBS as a negative control according to 120 manufactures directions (BD Pharmingen). 121 7 145
RNA extraction and quantitative real-time PCR 146
Total RNA was harvested using QIAGEN RNeasy Kit (QIAGEN, Hilden, Germany). Following 147 RNA extraction, cDNA synthesis was performed using High Capacity RNA-to-cDNA Kit 148 (ThermoFisher). qRT-PCR was carried out on equal concentrations of cDNA for each sample using 149 iTaq Universal SYBR Green Supermix. All primers can be found in supplemental materials and 150 methods. 151 152
Mass Spectrometry 153
For global proteome quantification, B220 + splenocytes were isolated from 3 mice per 154 genotype. Samples were prepared for and TMT labeled per manufacturer's protocol 155 (ThermoScientific TMT10plex Mass Tag Labeling Kits). Following TMT labeling, acetonitrile 156 was removed by speedvac and samples were resuspended in 0.1% trifluoroacetic acid (TFA). 157
Sample cleanup with C18 tips was performed per manufacturer's protocol (Pierce). Sample 158 concentrations were re-quantified (Pierce Quantitative Colorimetric Peptide Assay kit) and then 159 combined in equal concentration. Following combination, samples were dried by speedvac and 160 fractionated by ThermoScientific high pH reverse phase fractionation kit following 161 manufacturer's protocol for TMT. Resulting fractions were run in a speedvac to dryness and 162 resuspended in 0.1% Formic Acid for mass spectrometry (MS) analysis (see supplemental 163 methods cross-sectional genomic profiling of multiple lymphoma subtypes, we identified UBR5 as one of 8 183 genes that had a significantly higher frequency of mutation in MCL compared to other lymphoma 184 subtypes. These mutations were observed in 21 out of 196 MCL tumors (10.7%) and 15 out of 559 185 tumors (2.7%) of other histologic subtypes. However, mutations within the HECT domain were found 186 only in MCL tumors ( Figure 1B ). 18 Mutations within the HECT domain of UBR5 are therefore a 187 disease-specific genetic feature of MCL. 188 189
Generation of a conditional UBR5 HECT domain mutant. 190
Since the role of Ubr5 in lymphopoiesis is unknown, we first evaluated the expression of Ubr5 191 in B cell sub-groups during development by purifying pro, pre, and immature B cells from BM of 6-9
week-old C57/BL6 wild-type (WT) mice. Additionally, transitional, follicular, and marginal zone B cell 193 populations were purified from spleens. The pro B cell population showed lowest expression of Ubr5 194 at both the RNA and protein level, whereas the highest expression of Ubr5 was found in mature 195 splenic populations (follicular and marginal B cells) ( Figure 1B HECT domain and mimicking mutations found in MCL patients ( Figure 1D ). 20 We first crossed our 203
Ubr5 ΔHECT/+ mice to E2A CRE ;Ubr5 ΔHECT/+ mice that delete in early embryogenesis. 19, 21 As with null 204 mice, E2A CRE ;Ubr5 ΔHECT/ΔHECT were not viable. In contrast to Ubr5-null mice, 3 of 48 pups found dead 205 at birth were E2A CRE ;Ubr5 ΔHECT/ΔHECT , suggesting the HECT domain is not required for embryogenesis 206 and early stages of hematopoiesis ( Figure 1E -F). 207 208 Since E2A CRE ;Ubr5 ΔHECT/ΔHECT mice die prior to or at birth, to study B cell development we 209 crossed Ubr5 ΔHECT/∆HECT mice to Mb1 WT/CRE; Ubr5 ΔHECT/∆HECT , which deletes in early B-lymphocytes 210 ( Figure 1G ). 22 To determine the specific loss of the HECT domain, we performed qRT-PCR with 211 primers flanking the HECT domain and primers amplifying a region on the N-terminus in B220 + 212 splenocytes. qRT-PCR showed no decrease in Ubr5 expression, but significant decrease in Ubr5 213 HECT domain expression ( Figure 1H ). These studies demonstrate the loss of HECT domain of UBR5 214 targeted mice. 215
Impaired B cell maturation following deletion of UBR5 HECT domain.. 217
Early B cell development occurs in the BM compartment so we examined BM B cells in 6-218
week-old Mb1 WT/CRE ;Ubr5 ΔHECT/∆HECT mice. In Ubr5 ΔHECT/ΔHECT and Ubr5 ΔHECT/WT mice, the number of 219 total BM cells and frequency of B220 + B cells showed no significant difference compared to their WT 220 littermates ( The B1 population is responsible for innate immunity and is the first line of defense for infection. 241
In spleen, the B1 population was reduced by almost 2-fold in Ubr5 ΔHECT/ΔHECT mice and when further 242 separated into B1a and B1b, the reduction was exclusively found in the B1a subpopulation ( Figure  243 3K-M). We further evaluated B1 populations in the peritoneal cavity and found a ~75% reduction in 244 B1 cells, mainly from a reduction of B1a cells (Supplemental Figure 2 ). These findings demonstrate 245 a significant loss of populations required for innate immunity with loss of B1 and marginal zone B cells 246 following deletion of the HECT domain of Ubr5. 247 248
Alterations in follicular B cell subsets and activation of B cells. 249
Evaluating cell surface markers on the follicular B cell population, we found that 250
Ubr5 ΔHECT/ΔHECT follicular B cells had abnormal protein expression with low IgD and high IgM 251 compared to their WT littermates ( Figure 4A-B ). The follicular population in Ubr5 ΔHECT/ΔHECT mice also 252 had high CD23 protein expression, but normal expression of CD5 and CD1d on follicular B cells 253 ( Figure 4A -B). To further define alterations in the B cell compartment, we analyzed cell cycle status. 254
While follicular B cells are typically in the resting state, Ubr5 ΔHECT/ΔHECT cells are more quiescent and 255 had increased cells in G0 for both transitional and mature B cells (Supplemental Figure 3A) . 256
Additionally, staining with cellular proliferation marker Ki67 on spleen sections showed a reduction of 257 formation can be induced, we immunized 6-week-old mice with SRBC. Eight days following 265 immunization, we performed immunohistochemical (IHC) analysis on spleens with peanut agglutinin, 266 a GC marker. Staining revealed a significant decrease in overall number and size of GCs in 267
Ubr5 ∆HECT/∆HECT mice, but in white pulp with GCs, there were multiple small GCs ( Figure 4C ). Only 268 ~65% of white pulp in spleens of Ubr5 ΔHECT/ΔHECT mice contained GCs compared to ~83% in WT 269 littermate controls. We evaluated the ability of follicular B cells to terminally differentiate into plasma 270 cells within PB and found a ~50% reduction of B cells and plasma cells ( Figure 4D The HECT domain of UBR5 is thought to be required for its ubiquitination activity implicating 280 deletion could lead to increased accumulation of UBR5 substrates targeted for degradation by the 281 proteasome. To quantitatively determine protein differences in Ubr5 ΔHECT/ΔHECT versus WT littermates, 282
we labeled splenic B220 + cells with tandem mass tags (TMT), combined samples in equal 283 13 concentrations, and analyzed by MS ( Figure 5A ). Proteomic analysis identified 15,584 unique 284 peptides, 2,797 quantifiable proteins, and 1,675 proteins with greater than or equal to three unique 285 peptides. We identified 143 proteins that were either significantly decreased or enriched in 286 Ubr5 ΔHECT/ΔHECT B220 + splenocytes ( Figure 5B and Supplementary Table 2 ). Principle component 287 analysis (PCA) plot showed protein isolated from 3 independent mice from either genotype clustered 288 together, but that the two independent genotypes clustered separately ( Figure 5C ). In addition, 289 identified proteins were distributed in different cellular compartments ( Figure 5D ). Of the differentially 290 expressed proteins, 104 ≥1.3 fold significantly overexpressed proteins were enriched for proteins 291 associated with mRNA processing, RNA splicing, and mRNA splicing via the spliceosome, whereas 292 the 39 ≤0.70 fold significantly decreased proteins in spleen B220 + cells from Ubr5 ΔHECT/ΔHECT were 293 proteins associated with immune system process and protein transport ( Figure 5E -G). As suggested 294 by flowcytometry, IgD protein was the highest down-regulated protein following deletion of Ubr5 HECT 295 domain ( Figure 5E ). CD22, which is associated with B cell activation, was also down-regulated in 296 correlation with the follicular B cell phenotype in Ubr5 ΔHECT/ΔHECT mice ( Figure 5E ). Intriguingly, the 297 second highest expressed protein in splenic B cells of Ubr5 ΔHECT/ΔHECT was UBR5 ( Figure 5E -F). 298
Proteomic profiling revealed an increase in proteins associated with mRNA splicing in B cells lacking 299 HECT domain of UBR5 suggesting a novel role of UBR5 in mRNA splicing. 300
301
To identify putative substrates and interacting partners of UBR5 in MCL, we performed 302 immunoprecipitation followed by mass spectrometry (IP-MS) utilizing human MCL patient derived cell 303 lines, Jeko1 and Mino ( Figure 6A ). 24, 25 We identified 115 proteins with >3 unique peptides and, similar 304 to our TMT analysis, gene ontology analysis showed proteins enriched in mRNA splicing via the 305 spliceosome ( Figure 6B and Supplementary Table 3 ). Comparing MS datasets from TMT labeled 306 proteins and endogenous IP-MS revealed 89 proteins overlapping and seven proteins were up-307 regulated in the TMT study including UBR5 (Figure 7 D-E). Intriguingly, all six of the other identified 308 proteins are associated with mRNA splicing (SF3B3, SMC2, PRPF8, DHX15, SNRNP200, and 309 EFTUD2). These proteins are classified as core spliceosome components including U2 (SF3B3) and 310 associated U5 small nuclear ribonucleoprotein (snRNP) complex (EFTUD2, SNRNP200, and PRPF8) 311 ( Figure 6E ). Of the identified proteins, none have previously been characterized as UBR5 interactors 312 or substrates, suggesting a novel pathway of UBR5 regulation and the identification of potential novel 313 UBR5 substrates. 314 315
Alterations in splicing factors and splicing in B cells. 316
UBR5 has been implicated in a number of cellular processes including cell cycle (CDK9), DNA 317 damage (RNF168), and cell division (BUB3). [5] [6] [7] 26 BUB3 was found in the quantitative MS analysis; 318 however, accumulation was not seen in cells with deletion of Ubr5 HECT domain (Supplementary 319 Table 1 ). In addition, western blot confirmed that BUB3, CDK9, and RNF-168 did not accumulate in 320
Ubr5 ΔHECT/ΔHECT B220 + splenocytes ( Figure 7A ). Flowcytometry validated cell surface markers 321 associated with activation and maturation, CD22 and IgD, expression was significantly decreased in 322 total B220 + splenocytes ( Figure 7B-C) . UBR5 was the second highest expressed protein in the MS; 323 however, none of the identified peptides had coverage within the HECT domain (data not shown). To 324 confirm overexpression of UBR5 protein, we performed IHC and western blot analysis and found 325 higher protein expression of UBR5 in Ubr5 ΔHECT/ΔHECT spleens ( Figure 7A and D) . In order to determine 326 if loss of HECT domain leads to stabilization of the protein, we performed half-life analysis with 327 cycloheximide treatment. Ubr5 ΔHECT/ΔHECT B220 + splenocytes had higher protein expression due to 328 stabilization of the protein ( Figure 7E ). These studies validate the MS findings that known substrates 329 do not accumulate and loss of the HECT domain leads to overexpression and stabilization of UBR5. 330
331
To evaluate protein overexpression of RNA splicing components, we performed western blot 332 analysis on B220 + splenocytes. Ubr5 ΔHECT/ΔHECT B220 + splenocytes had increased expression of 333 EFTUD2, SMC2, and PRPF8 ( Figure 7F ). Because three of the identified proteins EFTUD2, 334 SNRNP200, and PRPF8 are part of the U5 snRNP complex, we wanted to determine whether UBR5 335 elutes with the U5 complex. We performed glycerol density gradient and found that EFTUD2, 336 SNRNP200, PRPF8, and UBR5 eluted in fractions 15-19 suggesting they are found in the same 337 complex ( Figure 7G) . IgD transcripts in Ubr5 ΔHECT/ΔHECT follicular B cells ( Figure 7H ). It was previously shown that mRNA of 344 Zinc Finger Protein 318 (Zfp318) has two known splice variants. 27 It is thought that the longer 345 transcript form containing exon 1-10 plays a key role in alternative splicing of immunoglobulin heavy 346 chain locus. We found decreased expression of transcript spliced from exon 7 to exon 11 and aberrant 347 variant transcripts in Ubr5 ΔHECT/ΔHECT follicular B cells, and decreased transcript containing exon 7 to 348 exon 9 suggesting expression of Zfp318 splice variants may also be contributing to B cell defects 349 ( Figure 7H ). These studies demonstrate that loss of HECT domain leads to increased expression of 350 spliceosome components and aberrant splicing. IgM occur. In addition, markers of mature naïve B cells, CD21 and CD23, have multiple splice 379 variants regulated by alternative splicing. 32, 33 Our studies find that in transitional and follicular B 380 cell populations, CD23 has altered expression, which may be due to splicing. Importantly, 381 expression of SF3B3 identified in our MS has been suggested to lead to alternative splicing of Ezh2 382 and promote tumorigenesis. 34 In addition, EZH2 has been previously shown to play a key role in 383 germinal center formation and EZH2 mutations promote lymphoid transformation. 35 Furthermore, 384 SF3B1, another component of the U2 snRNP complex that interacts with SF3B3 is frequently 385 mutated in chronic lymphoblastic leukemia and a variant of Myelodysplastic Syndrome, suggesting 386 that dysregulation of this complex may be important for development of hematopoietic 387 malignancies. 36, 37 Although these studies suggest a role of UBR5 in the spliceosome, further 388
investigation is required to determine if ubiquitination activity is required or whether UBR5 acts as 389 a scaffolding protein during splicing. 390
391
Loss of the HECT domain of UBR5 leads to stabilization and overexpression which could be 392 due to UBR5 potentially undergoing self-ubiquitination. 38 Also, UBR5 is predicted to bind RNA 393 further supporting its role in RNA splicing. 38 More importantly these studies identifying the 394 consequences of UBR5 HECT domain loss on alternative splicing in the immune system not only 395 reveal mechanisms regulating B cells development, but since ~18% of MCL patient genomes 396 contain UBR5 mutations, it may lead to further understanding of lymphoma transformation and 397 provide a potential therapeutic target. Overall, our findings reveal a novel mechanism of regulation 398 
